Welcome to the first edition of Glance at its new home, Eyes On Eyecare.
Glance is still the weekly email you know and love, but you'll see a lot of cool things coming up, starting with the new Glance website, where you can easily find all previously written articles as well as daily news.
If you're new here, I founded Glance in 2016 as an easy way to keep doctors up-to-date with clinically relevant news and research. Give me 5 minutes in your day, and I'll keep you up-to-date for the week!
Before we dive into 2023....let's recap what happened in 2022.
A lot! There are several potential FDA approvals on the docket:
ADX-2191 for primary vitreoretinal lymphoma
Eyenovia MydCombi ophthalmic spray for pupil dilation
NOV03 for meibomian gland dysfunction
Nyxol for mydriasis reversal
PDP-716 for glaucoma
Reproxalap for dry eye disease
Syfovre for geographic atrophy
TP-03 for demodex
Zimura for geographic atrophy
I hope you all had a wonderful New Year! See you next week!